Marshall Islands
Tuberculosis profile
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.058 (<0.01–0.24) 111 (1.4–448)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0.73 (0–8.2)
Prevalence  (includes HIV+TB) 0.57 (0.028–1.9) 1 079 (54–3 565)
Incidence  (includes HIV+TB) 0.3 (0.058–0.74) 572 (110–1 404)
Incidence (HIV+TB only) <0.01 (0–0.015) 2.6 (0–29)
Case detection, all forms (%) 48 (20–250)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 54 (40) Relapse 4 (67)
Smear-negative 39 (29) Treatment after failure 0 (0)
Smear-unknown / not done 14 (10) Treatment after default 0 (0)
Extrapulmonary 29 (21) Other 2 (33)
Other 0 (0)      
Total new 136   Total retreatment 6  
           
Other (history unknown) 5        
Total new and relapse 140   Total cases notified 147  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.3 0.8 1.6
Age < 15 0 19 15
Laboratories 2012
Smear (per 100 000 population) 5.7
Culture (per 5 million population) 95.1
Drug susceptibility testing (per 5 million population) 95.1
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 88   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 80  
Retreatment 100  
TB/HIV 2012 Number (%)
TB patients with known HIV status 88 (60)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 4.1 (0.86–12) 0 (0–98)
MDR-TB cases among notified pulmonary
TB cases
4 (1–12) 0 (0–6)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 73 (135%) 0 (0%) 73
Laboratory-confirmed MDR-TB cases 3 0 3
Patients started on MDR-TB treatment     4
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-19 Data: www.who.int/tb/data